



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IDS/#5
51831AUSM1
3/27/02
RECEIVED
MAR 25 2002
TECH CENTER 1600/2900

In re Application of :
Lau et al. :
Serial No. 09/838,785 : Group Art Unit 1615
Filed: April 20, 2001 : Examiner Not yet known
For DNA ENCODING A NOVEL PROST 03 POLYPEPTIDE

Assistant Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicants' duty of disclosure under 37 CFR §1.56 (a), Applicants direct the attention of the Office to the following documents, which are listed on attached modified Form PTO-1449 (1 page). The undersigned agent certifies that each item of information contained in this Supplemental Information Disclosure Statement was cited in an International Search Report, mailed March 21, 2002, for the PCT application corresponding to the above-identified patent application. These items are being brought to the attention of the Office within three months from their citation in the International Search Report in accordance with 37 CFR 1.97 (e) (1).

This supplemental IDS is being filed before the mailing of a first Office Action on the merits as described in 37 CFR §1.97(b). Therefore, it is believed that no fee is required under 37 CFR 1.97(b) (3).

The references are:

1. PCT Application WO 98/37093 (Corixa Corporation), published August 27, 1998; Compounds for Immunotherapy of Prostate Cancer and Methods for Their Use.
2. PCT Application WO 98/50567 (Abbott Laboratories), published November 12, 1998; Reagents and Methods Useful for Detecting Diseases of the Prostate.
3. PCT Application WO 99/67384 (Incyte Pharmaceuticals), published December 29, 1999; Prostate Cancer-Associated Genes.
4. PCT Application WO 01/34802 (Corixa Corporation), published May 17, 2001; Compositions and Methods for the Therapy and Diagnosis of Prostate Cancer.

Copies of the above-listed documents are provided herewith.

Applicants make no admission by the citation of these references that any of them necessarily constitute "prior art" to the application filed herewith.

The Examiner is respectfully requested to consider these documents and to indicate that this has been done by initialling and returning a copy of the modified Form PTO-1449 filed herewith to Applicants, in accordance with MPEP 609.

Respectfully submitted,

Wendy L. Washtien

Wendy L. Washtien, Ph.D.

Agent for Applicants

Reg. No. 36,301

Berlex Biosciences
15049 San Pablo Avenue
P.O. Box 4099
Richmond, CA 94804-0099
Telephone: (510) 262-5411
Fax: (510) 262-7095
Date: March 8, 2002

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on March 14 2002.

Carole J. Smith
Carole J. Smith

March 14, 2002
Date of Signature

PATENT
Case: 51831/ASM1

PATENT
MAR 2 5 2002
TECH CENTER 1600/2900

1615
#5
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Lau et al.

Serial No. 09/838,785

Filed: April 20, 2001

For: **DNA Encoding a Novel Prost 03 Polypeptide**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL OF SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT (37 CFR 1.97(b)(1))

Transmitted herewith for filing in the above-entitled patent application is the following.

1. Supplemental IDS
2. Form 1449 with Reference
3. Return postcard

Deposit Fee Authorization

Any fee which may be required should be charged to Deposit Account No. 02-2117. This is not, however, an authorization to pay the issue fee. A duplicate of this document is enclosed.

Respectfully submitted,

Wendy L. Washtien

Wendy L. Washtien
Agent for Applicants
Registration No. 36,301

Date: March 14, 2002

Berlex Biosciences
15049 San Pablo Avenue
P.O. Box 4099
Richmond, California 94804-0099
510.262-5411 Telephone
510.262-7095 Facsimile
wendy_washtien@berlex.com